Partnerships, Licensing, Investments and M&A Deals and Trends for October 2018 in Pharmaceuticals

Published : Dec-2018

No. of Pages : 79

order by fax Inquire before Buying request discount

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2018 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2018 12
2.2.1 AstraZeneca Enters into Co-development Agreement with Innate Pharma 12
2.2.2 Novartis to Acquire Endocyte 12
2.2.3 Janssen Pharma Enters into Research and Option Agreement with Arrowhead Pharma 13
2.2.4 Grunenthal Receives Rights for Nexium from AstraZeneca 13
2.2.5 Dragonfly Therapeutics Enters into Collaboration Agreement with Merck 14
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2018 15
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2018 16
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2018 17
3.1.1 Top M&A Deals in October 2018 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2018 - October 2018 19
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2018 20
3.2.1 Top Equity Offering Deals in October 2018 21
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2018 - October 2018 22
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2018 23
3.3.1 Top PE/VC Deals in October 2018 24
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2018 25
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2018 26
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016-October 2018 28
3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016-October 2018 29
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2018 30
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2018 - October 2018 31
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 32
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2018 33
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 34
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2018 - October 2018 35
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2018 - October 2018 36
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 37
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2018 38
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2018 38
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 39
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2018 - October 2018 40
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2018 - October 2018 41
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2018 - October 2018 42
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2018 - October 2018 44
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2018 45
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2018 45
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2018 46
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 47
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2018 47
5.1.1 Oncology - Deals of the Month 48
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2018 49
5.2.1 Central Nervous System - Deals of the Month 50
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2018 52
5.3.1 Infectious Diseases - Deals of the Month 53
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2018 55
5.4.1 Cardiovascular - Deals of the Month 56
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2018 58
5.5.1 Immunology - Deal of the Month 59
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, October 2018 60
5.6.1 Gastrointestinal - Deals of the Month 61
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, October 2018 62
5.7.1 Metabolic Disorders - Deals of the Month 63
6 Deal Summary by Geography 64
6.1 Pharmaceuticals & Healthcare, North America Deals, October 2018 64
6.1.1 North America - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2018 67
6.2.1 Europe - Deals of the Month 68
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2018 70
6.3.1 Asia-Pacific - Deals of the Month 71
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2018 72
6.4.1 Rest of the World - Deals of the Month 73
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 75
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2018 - October 2018 75
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2018 - October 2018 76
8 Further Information 77
8.1 Methodology 77
8.2 About GlobalData 78
8.3 Contact Us 78
8.4 Disclosure information 78
8.5 Disclaimer 79

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 11
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2018 12
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2018 16
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 18
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2018 18
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 - October 2018 19
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 21
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2018 21
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 22
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 24
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2018 24
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2018 - October 2018 25
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2018 27
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 28
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2018 - October 2018 29
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 30
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 31
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 32
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 33
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 34
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 - October 2018 36
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2018 - October 2018 37
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 38
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 39
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 40
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2018 41
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 - October 2018 43
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 44
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2018 45
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2018 45
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2018 46
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 48
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 50
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 53
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 56
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 59
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 61
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 63
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 65
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 68
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 71
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 73
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 75
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 76

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2018 15
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2018 16
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 17
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 - October 2018 19
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 20
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 22
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 23
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2018 - October 2018 25
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2018 26
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2018 27
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 28
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 30
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 32
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 - October 2018 35
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2018 - October 2018 36
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 37
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 38
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 39
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 40
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2018 - October 2018 41
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2018 - October 2018 42
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2018 - October 2018 43
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 44
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 47
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 49
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 52
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 55
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 58
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 60
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 62
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 64
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 67
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 70
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 72
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 75
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2018 - October 2018 76

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Partnerships, Licensing, Investments and M&A Deals and Trends for October 2018 in Pharmaceuticals

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027